Federal contract award

75N93020F00002

TO DETERMINE THE ANTIVIRAL INHIBITORY EFFECT AND CYTOTOXICITY OF EXPERIMENTAL ANTIVIRAL COMPOUNDS AGAINST VIRUSES LISTED IN GROUPS 4, 5, 6, AND 7, AS WELL AS OTHER RAPIDLY EMERGING VIRUSES THAT UTILIZE THE SAME ASSAY METHODOLOGY.

Research the contractorView USAspending sourceSave to my pursuit research

Award details

Obligations, current value and potential value describe different measures; they are never added together.

FieldReported value
AgencyDepartment of Health and Human Services
OfficeNATIONAL INSTITUTES OF HEALTH NIAID
NAICS541714 — Research and Development in Biotechnology (except Nanobiotechnology)
PSCAN11 — HEALTH R&D SERVICES; HEALTH CARE SERVICES; BASIC RESEARCH
Parent award / vehicle75N93019D00021
Set-asideNot reported
Pricing typeFIRM FIXED PRICE
Obligations$618.5K
Current contract value$618.5K
Potential contract value / ceiling$767.2K
Start dateSep 17, 2020
Current end dateSep 20, 2021
Potential end dateSep 20, 2021
Latest award activityApr 29, 2021
Source loadedSep 26, 2026

Funding and modification history

Showing the latest 3 of 3 loaded transactions. Negative values are deobligations.

DateModificationObligation changeDescription
Apr 29, 2021P00002$0TO DETERMINE THE ANTIVIRAL INHIBITORY EFFECT AND CYTOTOXICITY OF EXPERIMENTAL ANTIVIRAL COMPOUNDS AGAINST VIRUSES LISTED IN GROUPS 4, 5, 6, AND 7, AS WELL AS OTHER RAPIDLY EMERGING VIRUSES THAT UTILIZE THE SAME ASSAY METHODOLOGY.
Nov 13, 2020P00001$0TO DETERMINE THE ANTIVIRAL INHIBITORY EFFECT AND CYTOTOXICITY OF EXPERIMENTAL ANTIVIRAL COMPOUNDS AGAINST VIRUSES LISTED IN GROUPS 4, 5, 6, AND 7, AS WELL AS OTHER RAPIDLY EMERGING VIRUSES THAT UTILIZE THE SAME ASSAY METHODOLOGY.
Sep 17, 20200$618.5KTO DETERMINE THE ANTIVIRAL INHIBITORY EFFECT AND CYTOTOXICITY OF EXPERIMENTAL ANTIVIRAL COMPOUNDS AGAINST VIRUSES LISTED IN GROUPS 4, 5, 6, AND 7, AS WELL AS OTHER RAPIDLY EMERGING VIRUSES THAT UTILIZE THE SAME ASSAY METHODOLOGY.

Research next steps

  1. Confirm the ordering vehicle and your eligibility or a qualified teaming route.
  2. Review the award scope and buyer evidence before making a bid/no-bid decision.